OrchestratePharma signs agreement with Cellix Bioscience for CSU

OrchestratePharma has signed a strategic agreement with Cellix Bioscience to advance the clinical development of fexofenadine-based treatments for chronic spontaneous urticaria (CSU).

Chronic spontaneous urticaria is a debilitating condition characterized by recurring hives that appear without a specific external trigger. Current treatment options remain limited for many patients, highlighting the need for new therapeutic approaches.

This agreement brings together OrchestratePharma's expertise in fexofenadine-based drug development with Cellix Bioscience's capabilities in dermatological research and clinical development.

The collaboration aims to explore novel formulations and delivery mechanisms that could provide superior efficacy compared to existing treatments.